Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Q2 2023 Earnings Presentation
26 slides from Telix Pharmaceuticals's earnings presentation, Jul 19, 2023
Slide 1: Q2 2023 Quarterly Business Update
Q2 2023 Quarterly Business Update Telix Pharmaceuticals (ASX:TLX) 19 July 2023 Illustration of TLX250-CDx binding to carbonic anhydrase IX
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied,
Slide 3: Presenters
Presenters Kyahn Williamson Dr Christian Behrenbruch Dr Colin Hayward Darren Smith SVP Investor Relations Managing Director and Group Chief Medical Group Chief Financial and Corporate Group Chief Executive Officer Officer Communications Officer 3
Slide 4: Q2 2023: Operational highlights
Q2 2023: Operational highlights Aligned to our growth strategy and reinforcing our leadership in urology GROWING DEMAND PREPARING TO MOMENTUM PIPELINE FOR ILLUCCIX® LAUNCH TWO BUILDING IN THE EXPANSION & PRODUCTS IN 20241 CLINIC INNOVATION • Total revenue up 21%, • Major operational • ProstACT GLOBA
Slide 5: Q2 2023: Financial metrics
Q2 2023: Financial metrics A solid foundation for growth Total revenue comparison to previous periods Q2 2023 $120.7M Up 21% on Q1 Net operating Gross Customer Cash Q1 2023 cash inflow margin receipts balance $100.1M $10.8M 64% $112.2M $131.7M Improvement of Stable selling Improved As at 30 June $8.
Slide 6: Illuccix Commercial Update
Illuccix® Commercial Update
Slide 7: Sustained, strong revenue growth in U.S. market
GROWING DEMAND Sustained, strong revenue growth in U.S. market FOR ILLUCCIX Illuccix performing strongly in the growing PSMA-PET1 imaging market • Revenue from U.S. sales of Illuccix up 19% to $116.0M (US$77.6M) on the prior quarter Revenue from U.S. sales of Illuccix (AU$M) 130.0 • Adoption of PSMA
Slide 8: 68Ga-PSMA-11 PET in new and updated guidelines
GROWING DEMAND 68Ga-PSMA-11 PET in new and updated guidelines FOR ILLUCCIX Continues to reinforce advantages of 68Ga- over 18F-based PSMA imaging 180 Figure 1: Latest independent procedure guidelines 160 Localisation of tumour 140 lesions in patients with Benign regions (n) highlight lower nonspecif
Slide 9: Financial Commentary
Financial Commentary OTelix —— ae
Slide 10: Positive operating cash flow trend continues
Positive operating cash flow trend continues Third consecutive quarter of net cash inflow from operating activities Cash flow from operating activities ($M) 20.0 • Cash increased to $131.7M at 30 June 2023 (compared to $121.4M at 31 March 2023) 10.0 10.8 1.6 2.4 • Quarterly operating cash flow impro
Slide 11: Sales performance and controlling operating expenditure
Sales performance and controlling operating expenditure Funding focused investment in priority programs Product-related revenue ($M) and gross margin • Gross margin remains stable from Q1 2023, reflecting percentage 140 64% 66% stable selling prices and manufacturing processes 120 63% 63% 64% 61% 11
Slide 12: Continued growth in revenue and adjusted EBITDAR
Continued growth in revenue and adjusted EBITDAR1 Quarterly growth continues Total revenue ($M) 140.0 120.0 • Revenue $120.7M, a 21% improvement on $100.1M 120.7 100.0 in the prior quarter 100.1 80.0 • Total revenue is commercial sales of Illuccix plus 60.0 79.0 57.1 other revenue from pre-commercia
Slide 13: Q2 2023 Program highlights
Q2 2023 Program highlights 13
Slide 14: TLX250-CDx: Further data supports expanded utility
PREPARING TO TLX250-CDx: Further data supports expanded utility LAUNCH IN 2024 Scale-up underway to support launch in 2024 New ZIRCON data1 presented at SNMMI2 • TLX250-CDx PET/CT detected more lesions in liver and bone than diagnostic CT imaging alone • 25 patients had ≥1 extrarenal lesions detecte
Slide 15: TLX101-CDx for imaging of glioma (18F-FET PET)
PREPARING TO TLX101-CDx for imaging of glioma (18F-FET PET) LAUNCH IN 2024 Unmet need for delineating progressive disease from treatment-induced changes ROC analysis of 80 U.S. New Drug Application (NDA) in progress for patients with grade submission in 2023 3/4 glioma or brain metastases • Initial
Slide 16: Clinical development highlights
MOMENTUM Clinical development highlights BUILDING IN THE CLINIC Progress across multiple therapeutic trials Renal cancer imaging Prostate cancer Glioma imaging Rare diseases and therapy therapy and therapy portfolio • First patients dosed in • A total of 30 patients • IPAX-2 study – all sites • Prep
Slide 17: Phase II STARBURST study: First patients dosed
MOMENTUM Phase II STARBURST study: First patients dosed BUILDING IN THE CLINIC Targeting advanced metastatic tumours in multiple cancer types • STARBURST is looking at CAIX- expressing tumour types in a refractory setting to assess whether tumour sites can be visualised using TLX250-CDx PET/CT imagi
Slide 18: Collaboration with Merck KGaA
MOMENTUM Collaboration with Merck KGaA BUILDING IN THE CLINIC TLX250 + DNA damage response inhibitor (DDRi) study now dosing patients Summary of pre-clinical results in Xenograft mice2 • Phase Ib dose expansion study to evaluate safety, dosing and activity of TLX250 in combination with DNA-PK inhibi
Slide 19: Leadership in urologic oncology
PIPELINE EXPANSION Leadership in urologic oncology & INNOVATION End-to-end product offering (Dx + Sx + Tx) h Diagnosis & Staging Surgical Therapy Technologies TLX250-CDx Telix AITM 19
Slide 20: Acquisition of Lightpoint Medical
PIPELINE EXPANSION Acquisition of Lightpoint Medical1 & INNOVATION Bringing molecular imaging into the operating room is a major opportunity • The urologist (surgeon) is a key stakeholder in the management of prostate cancer: the core Illuccix indications “book end” a surgical procedure • ~96,000 ra
Slide 21: A differentiated AI platform: Telix AI
PIPELINE EXPANSION A differentiated AI platform: Telix AI™ & INNOVATION The Dedicaid acquisition adds a new dimension of clinical support Reader Support1 Clinical Decision Support2 Increases efficiency Predicts disease and reproducibility of outcomes including imaging assessments potential risk, sev
Slide 22: Telix Manufacturing Solutions (TMS)
PIPELINE EXPANSION Telix Manufacturing Solutions (TMS) & INNOVATION Stage 1 build-out complete 300 sqm 2 x quality control labs At 2,800 sqm, TMS is one of Europe’s largest warehousing radiopharmaceutical production facilities The site will enable: 1 x Alpha R&D lab 1 x Beta R&D lab • Improved acces
Slide 23: Outlook
x ‘e] 2 ad =| O
Slide 24: Our near-term strategic priorities
Our near-term strategic priorities Delivering clinical and commercial outcomes to drive benefits for patients and shareholders Leadership in urologic Launch in Unlock the value in the oncology neuro-oncology therapeutic pipeline Demonstrates our ability to Delivery of clinical milestones, End-to-end
Slide 25: Recent and upcoming milestones
Recent and upcoming milestones Illuccix® - ProstACT Four key continued GLOBAL patient NDA for brain recruitment and BLA submission cancer imaging catalysts revenue growth for TLX250-CDx and global data readout (TLX101-CDx) rollout ProstACT SELECT EXPECTED MILESTONES 2023 Additional Illuccix® Prostat
Slide 26: Thank you & questions
Thank you & questions Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com 26
Telix Pharmaceuticals — Q2 2023 Earnings Presentation on 6ix